Genetic prognostication and treatment selection in Multiple Myeloma. Kihyun Kim Department of Medicine Sungkyunkwan University Samsung Medical Center
|
|
- Rosa Taylor
- 5 years ago
- Views:
Transcription
1 Genetic prognostication and treatment selection in Multiple Myeloma Kihyun Kim Department of Medicine Sungkyunkwan University Samsung Medical Center
2 The International Congress of BMT 2018 COI disclosure Name of author : Kihyun Kim I have no personal or financial interests to declare. I have no financial support from an industry source at the current presentation.
3 Multiple Myeloma Kumar SK, et al. Leukemia
4 Clonal evolution & subclonal heterogeneity of myeloma Pawlyn et al. Nature reviews Cancer 2017, 17:534
5 high-risk cytogenetics in the era of novel agents Avet-Loiseau et al. Leukemia 2018, 32, 1267
6 Diagnostic techniques for cytogenetic abnormalities Conventional karyotyping Fluorescence in situ hybridization Purification of CD138-expressing plasma cells or dual staining for cytoplasmic immunoglobulin (Ig) and FISH Singe-nucleotide polymorphism based mapping arrays identify copy number variations (CNV). Translocations are not usually detected Array-based comparative genomic hybridization a tool for genome-wide classification of CNVs Gene expression profiling Next Generation Sequencing
7 Primary and secondary cytogenetic abnormalities in MM Kumar et al. Nat Rev Clin Oncol. 2018, 1759
8 Genetic lesions associated with high-risk multiple myeloma Class Lesion Genes affected Primary translocations Secondary translocations Copy number change Homozygous inactivation of TSGs Genetic changes associated with DNA repair deficiency Frequency in NDMM (approx. %) Change in Frequency at relapse Identifiable by ifish CNA GEP NGS t(4;14) MMSET 15 No change, t(14;16) MAF 3 clonal initiating Yes No Yes Yes t(14;20) MAFB 1.5 events MYC MYC 20 Increased Yes No No Yes JT1q BCL9, MCL1, IL6RA, CKS1B, ANP32E and others Isochromosome formation Many Unknown Unknown Hyperhaploidy Many Few Unknown Gain (1q) Del (1p) Genes located in the 1q transcriptional unit are: BCL9, MCL1, IL6RA, CKS1B, ANP32E and others Genes lost on 1p are: FAF1, CDKN2C, FAM46C, RPL5 and others Unknown Increased Yes No No Yes Gain: 30 Amp: 10 Increased 20 Increased Del (17p) TP53 and others 10 Increased RB1 2 TP53 4 Mutation +/ FAM46C 5 copy number change CYLD 3 Increased TRAF3 8 No Yes No Yes Yes Yes Yes Yes No Yes, with NGS No Yes with CNA Genome-wide LOH Many 5 Increased No No No Yes Pawlyn et al. Nature reviews Cancer 2017, 17:534
9 Common risk stratification approaches in MM Staging system Variables Stages International Staging System (ISS) Serum albumin and β 2 m levels I: serum albumin 3.5 g/dl and β 2 m <3.5 mg/dl II: neither stage I nor III III: β 2 m >5.5 mg/dl Revised International Staging Syst em (RISS) International Myeloma Working G roup (IMWG) risk staging msmart risk staging Gene-expression-based signatures Serum albumin, β 2 m, and LDH levels, and plasma cell FISH Serum albumin, β 2 m, and LDH levels, and plasma cell FISH Serum albumin, β 2 m and LDH levels, plasma cell FISH, and proliferation index UAMS Skyline 92 HOVON IFM I: ISS stage I, LDH normal, and standard-risk disease according to FISH II: neither stage I nor stage III III: ISS stage III plus abnormal LDH or high-risk disease according to FISH (del 17p and/or t(4;14) or t(14;16)) Low risk: ISS stage I or II, absence of t(4;14), del 17p13 and del 1q21, and <55 years of age Standard risk: all others High risk: ISS stage II or III and either t(4;14) or del 17p13 Standard risk: trisomies and/or t(11;14) Intermediate risk: t(4;14) or 1q amplification High risk: t(14;16), t(14;20), or del 17p Presence of alterations detected by each signature Kumar et al. Nat Rev Clin Oncol. 2018, 1759
10 Combined prognostic models of ISS and FISH IMWG MRC German Treatment Include both young patients (transplan t) and older patients (chemotherapy o nly) Young (intensive) and old patients (non-int ensive) with thalidomide-based combinatio n at induction and thalidomide maintenanc e on MRC IX trials Chemo-based induction followed b y HD Mel ASCT and maintenance Low-risk N Parameter ISS I/II with no adverse FISH ISS I/II with no adverse FISH or ISS I with 1 adverse FISH lesions ISS I with no adverse FISH % Patients 51% 38% 42% Int risk OS 76% at 4 years Median 67.8 months 72% at 5 years Parameter ISS III with no adverse FISH or ISS I an d t(4;14)/17p13 del ISS I with >1 adverse FISH lesions ISS II/III with 1 adverse FISH lesions or ISS III and n o adverse FISH ISS II/III with no adverse FISH or IS S I and t(4;14)/17p13 del % Patients 29% 48% 44% OS 45% at 4 years Median 41.3 months 62% at 5 years High-risk Parameter ISS II/III and t(4;14)/17p13 del ISS II/III with >1 adverse FISH lesions ISS II/III and t(4;14)/17p13 del % Patients 20% 14% 14% OS 33% at 4 years Median 19.4 months 41% at 5 years Chng et al. Leukemia, 2014, 269
11 Genetic markers t(4;14) and del17p, but not 1q gain or mutational data from TP53. The proportion of stage II is larger than stage I or III The high-risk group in the R-ISS classification comprised 10% and had a median PFS of 29 months and 5-year OS of 40%.
12 Genetic events that can be identified by FISH Primary genetic events Secondary genetic events IgH translocation Gene(s) Frequency (%) Deletion Gene(s) Frequency (%) t(4;14) FGFR3/MMSET 15 1p CDKN2C, FAF1, FAM46C t(6;14) CCND3 4 6q 33 t(11;14) CCND1 20 8p 25 t(14;16) MAF 4 13 RB1, DIS3 44 t(14;20) MAFB 1 11q BIRC2/BIRC3 7 Hyperdiploidy 30 14q TRAF q WWOX, CYLD 35 17p TP53 7 Gain Trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19, 21 NA 50 1q CKS1B, ANP32E 40 Sonneveld et al. Blood. 2016;127(24):
13 Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience Hebraud et al. Blood. 2015;125(13):2095
14 Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience Hebraud et al. Blood. 2015;125(13):2095
15 Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience Hebraud et al. Blood. 2015;125(13):2095
16 multiple cytogenetic high-risk abnormalities Binder et al. Blood Cancer Journal (2017) 7, e600
17 Monosomy 13 vs. del 13q Binder et al. Blood Cancer Journal (2017) 7, e600
18 Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations Blood. 2015;125(5):
19 Prediction of outcome in newly diagnosed myeloma Combined data of MRC IX (869) and NCRI XI (N=1036) Copy number abnormalidty & IgH translocation: MLPA (Multiplex ligation dependent probe amplification) and qrt-pcr a double-hit any two of the following: (1) t(4;14), t(14;16), t(14;20) (2) gain(1q) (3) del(17p) double-hit -ISS ultra high risk (ISS II or III and double-hit ; 12.0%) intermediate risk (ISS I and double-hit ; ISS II and 1 adverse lesion; ISS III and no or 1 adverse lesion; 44.1%) favourable risk groups (ISS I and no or 1 adverse lesion; ISS II and no adverse lesion; 43.9%). Shah et al. Leukemia (2018) 102
20 Prediction of outcome in newly diagnosed myeloma Shah et al. Leukemia (2018) 102
21
22 GEP-based prognostic signatures GEP signatures Methods Ref UAMS 70-gene Comparing the expression profiles of patients with top a nd bottom quartile of survival treatment on Total Therap y II Blood 2006; 109: IFM signature Centrosome index HZD cell death signature IL6-HMCL signature Model derived from iterative process of univariate cox an alysis, resampling analysis and then principle component analysis Based on expression of genes encoding components of t he centrosome Signature derived from genes homozygously deleted in myeloma as detected by array comparative genomic hybr idization 13 Genes signature build from genes accounted for heter ogeneity in human myeloma cells lines upon IL6 stimulati on J Clin Oncol 2008; 26: Blood 2008; 111: Clin Cancer Res 2010; 16: Haematologica 2011; 96: Proliferation index Based on proliferation genes Haematologica 2011; 96: EMC 92-gene signature Generated by supervised component analysis with simula ted annealing Leukemia 2012; 26: Chromosome instability genomic event count (CINGEC) signature Genes differentially expression between patients with the top quartile and bottom quartile of genomic complexity based on the number of acgh defined abnormalities incl uding both DNA gains and losses and breaks. PLoS One 2013; 8: e66361 Chng et al. Leukemia, 2014, 269
23 TC classification Bergsagel et al. Blood 2005, 296
24 UAMS classification Zhan et al. Blood. 2006, 2020
25 Clinical value of GEP-based molecular subtyping a data set of 1217 patients with multiple myeloma enrolled in Total Therapies TT2+: add thalidomide TT3a: bortezmib TT3b: lenalidomide maintenance Weinhold et al. Leukemia (2016) 30,
26 Clinical value of GEP-based molecular subtyping Weinhold et al. Leukemia (2016) 30,
27 Epigenetic inactivation of tumor suppressor genes Global methylation analysis MRC IX trial 195 genes with changes in methylation status the epigenetically regulated tumor modulating genes GPX3, RBP1, SPARC, and TGFBI. Kaiser et al. blood 2013,122(2):
28 203 Patients with MM Chapment et al. Nature, 2011, 470, Morgan et al. Nat Rev Cancer ;12(5):335 Lohr et al. Cancer Cell 2014, 25, 91
29 Common mutations in MM Gene Frequency (%) Function KRAS NRAS TP MAPK signalling pathway (cell survival and growth) MAPK signalling pathway (cell survival and growth) Tumour suppressor involved in response to DNA damage and apoptosis DIS3 11 Exosome endoribonuclease FAM46C ~11 Unclear BRAF 6 15 TRAF3 3 6 MAPK signalling pathway (cell survival and growth) NF-κB signalling pathway (cell survival and proliferation) ROBO1 2 5 Transmembrane receptor involved cell growth through crosstalk with MET signalling CYLD 2 3 NF-κB signalling pathway (cell survival and proliferation) EGR1 4 6 Transcription factor SP Antigen-response mechanisms in mature B cells FAT3 4 7 Cadherin superfamily member (cell adhesion) CCND1 3 Cell cycle progression
30 NGS 84 samples from 67 patients with MM exome sequencing, high-resolution copy-number arrays and cytogenetics Bolli et al Nat Commun. 2014;5:2997
31 Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma longitudinal study of 33 patients entered into Total Therapy protocols gene expression profiling high-resolution copy number arrays whole-exome sequencing Weinhold et al. Blood. 2016;128(13):1735
32 clonal evolution in homogeneously treated patients targeted sequencing of bone marrow plasma cells in 43 multiple myeloma patients at diagnosis and at relapse from exactly the same intensive treatment. Corre et al. Leukemia 2018 e-pub online
33 Mutational Spectrum, Copy Number Changes, and Outcome of NDMM 463 NDMM, MRC Myeloma XI trial 15 significantly mutated genes IRF4, KRAS, NRAS, MAX, HIST1H1E, RB1, EGR1, TP53, TRAF3, FAM46C, DIS3, BRAF, LTB, CYLD, and FGFR3. Mutations in the RAS (43%) and nuclear factor-b (17%) pathways are prognostically neutral Mutations in CCND1 and DNA repair pathway alterations (TP53, ATM, ATR, and ZNFHX4 mutations) are associated with a negative impact on survival. IRF4 and EGR1 are associated with a favorable overall survival. Walker et al. J Clin Oncol 33:
34 Mutational Spectrum, Copy Number Changes, and Outcome of NDMM Group 1, ISS I and II with no copy number and structural abnormality [CNSA] or mutation; Group 2, ISS III with no CNSA or mutation or ISS I, II, and III with one CNSA or mutation Group 3, two CNSAs or mutations regardless of their ISS) Mutation:including TP53, ZFHX4, CCND1, ATM and ATR, MYC translocations, and amp(1q). Walker et al. J Clin Oncol 33:
35 Myeloma Genome Project Whole genome/exome data N=1273 the Myeloma XI trial the Dana-Faber Cancer Institute/Intergroupe Francophone du Myelome the Multiple Myeloma Research Foundation CoMMpass study 63 mutated driver genes Increased number of driver mutations is associated with poor outcome Walker et al. Blood. 2018;132(6):
36 Walker et al. Blood. 2018;132(6): Copy number (CN) clusters CN cluster % Hyperdiploid, gains of 1q, 6p, expression of CCND2 CN cluster % hyperdiploid with gain of 11q and expression of CCND1, mutation of FAM46C inversely associated with gain of 1q CN cluster 3 5.6% associated with t(14;16), deletions of 1p, 8p, 13q, 14q, and 16q, and gain of 1q. CN cluster 4 5.2% associated with t(4;14), del13q, and del14q CN cluster 5 6.7% associated with t(4;14), del4p, del13q, and del14q, mutations of NFKBIA, MAX, and TRAF3. CN cluster 6 5.9% associated with deletions of 8p, 14q, and 16q, gain of 1q, and mutation of CYLD. CN cluster 7 7.9% associated with t(4;14) and t(14;16), the APOBEC signature, deletions of 11q and 13q, gain of 1q, and mutation of DIS3, delfgfr3 CN cluster % associated with t(11;14) and mutations of CCND1 and PRKD2, but not with any deletions or gains. CN cluster 9 4.8% associated with t(11;14) and gain of 11q as well as mutation of BRAF
37 A high-risk, Double-Hit, group of newly diagnosed myeloma Myeloma genome project N=1273 Exclude aged >75 Walker et al. leukemia e-pub online
38 A high-risk, Double-Hit, group of newly diagnosed myeloma 6.1% of the population median PFS = 15.4 months, median OS = 20.7 months Walker et al. leukemia e-pub online
39 Targeted Sequencing 47 gene multiple myeloma mutation panel(m 3 P) Genomic profiles to guide precision therapy Small amounts of DNA Deep coverage results 39 the top mutated genes Resistance to IMiDs (CRBN, CUL4A, CUL4B, DDB1 and IRF4), proteasome inhibitors (PSMG2, PSMB5) and glucocorticoid therapies (NR3C1) 72 untreated high-risk (del17p) MM patients Mutations in 78% of the patients. TP53 mutation was increased (28%) no mutations in FAM46C. British Journal of Haematology, 2015, 168, 507
40 Targeted sequencing of refractory myeloma 50 multidrug refractory multiple myeloma 88%, 78%, and 68% were refractory to an IMiD, a PI, or both 47 gene multiple myeloma mutation panel(m 3 P) an increased prevalence of mutations in the Ras pathway genes KRAS,NRAS, and/or BRAF(72%), as well as TP53 (26%), CRBN(12%), and CRBN pathway genes (10%) Kortum et al. Blood. 2016;128:1226
41 Targeted Sequencing N=418 N. Bolli et al leukemia 2018 e-pub
42 Integrative network analysis The MMRF CoMMpass study is a longitudinal, prospective observational study MMNet an integrated network of MM incorporating RNA-seq, WES, WGS and clinical data from CoMMpass IA7 Laguna et al. Leukemia (2018) 120
43 Integrative network analysis Laguna et al. Leukemia (2018) 120
44 CoMMpass: MMNet-based patient clusters Cluster No. of Pts Ex. upregulated genes Ex. downregulated genes UAMS Transloc Somat Mut CNA Mut Burd CCND1 82 (18.2%) CCND1, DTX1, PAX5 CCND2, MEIS2, NEDD4, CDK6, PRAME CD-1, CD-2 t(11;14) MAF 30 (6.6%) NUAK1, CCND2, MAF-A, IL21R, MAF NCAM1, GLI3, BMP4, DKK1 MF t(14;16) t(14;20) SYNE2 1q amp, 13q del, 16q del UP CCND3 2 (0.45%) CCND3, PRICKLE4, USP49 t(6;14) DOWN MMSET 76 (16.8%) CCND3/ del FGFR3, CCND2, CDC42BPA, CLEC11A, NUAK1, WHSC1 MAGEC1, LAG3, PAX5, CCND1 MS t(4;14) DIS3, MAX, FGFR3 1q amp, 1p del, 12 del, 13q del, 14q del, 22q del 4 (8.8%) CCND3, MAP1A, USP49, PRICKLE4 SMOX, TPRG1, NFATC4 t(6;14) 6 del, 8 del, 14q del CK 38 (8.4%) XIRP1, CXCL8, IL1R2, SEMA7A, TREM1, TUBB3, IL6, DUSP8, DUSP4, BCL6 CCR2, NEK2, TOP2A, CD28, CDK1 PR (inv.) HY/NRAS 118 (26.2%) CCR5, PRAME, GLI3, LAG3, FRZB, MEIS2 CCND2, CDR1, CDKN1C, IGF1R HY NRAS Hyperdiploidy (3, 5, 7, 9, 11, 15, 19, 21 amp) IMM 42 (9.3%) S100A8, S100A12, S100A9, CXCR1, CCND2 SETP4, ABCG2, PALD1, SIX4 MYC 29 (6.4%) PKHD1, MAGEA3, MAGEA12, ASS1, MYC CD44, MAF, NUAK1 t(8;14) 15q amp CC 29 (6.4%) CCND2, MAGEA3, MAGEC1, MAGEA6, MEIS2 CCND1, SATB1, PMAIP1, KIF19 PR LB, CD-1 (inv.) DST 1p del, 4 del, 13q del, 14q del, 16 del DOWN Laguna et al. Leukemia (2018) 120 UP
45 Spatial genomic heterogeneity in multiple myeloma Rasche et al. Nat Commun. 2017;8(1):268
46 Spatial genomic heterogeneity in multiple myeloma Rasche et al. Nat Commun. 2017;8(1):268
47 Large focal lesions is a strong independent prognostic factor in multiple myeloma Rasche et al. Blood. 2018;132(1):59
48 Circulating tumour DNA sequence analysis as an alternative to MM BM aspirates a hybrid-capturebased Liquid Biopsy Sequencing (LB-Seq) method targeted deep sequencing of all protein coding exons of KRAS, NRAS, BRAF, EGFR and PIK3CA genes in 64 cfdna specimens from 53 myeloma patients 83 ng of cfdna or less (13 samples had ng of cfdna available), extracted from 3 to 13ml (median 8.5ml) of blood plasma, Kis et al. Nat Commun ;8:15086.
49 Cell-free DNA sequencing Guo et al leukemia e-pub
50 Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma ultra-low pass whole genome sequencing (ULP-WGS) Manier et al. NATURE COMMUNICATIONS 2018, 9:1691
51 Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma Manier et al. NATURE COMMUNICATIONS 2018, 9:1691
52 Genetic interrogation of circulating MM cells at single-cell resolution Lohr et al. Sci. Transl. Med. 8, 363ra147 (2016)
53 Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data Fan et al. Genome research :1217
54 CD38-APC Myeloma transcriptome analysis in variable disease states Tumor cell enrichment by anti- CD138 Ab CD138- PE comparison Bone marrow in stable disease>>bone marrow in aggressive disease>> Refractory extramedullary Unpublished data
55 Transcriptional programs controlling the myeloma progression Ubpublished data
56 Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects Ubels et al. NATURE COMMUNICATIONS DOI: /s
57 Conclusion With advances of techniques and knowledge of myeloma pathogenesis novel ways for genetic prognostication have been tried. CNVs and translocations have a stronger impact on prognosis than mutations, but extended genotyping shows novel prognostic categories. Methods for treatment selection especially for high risk myeloma patients are still unmet needs.
Biology of high risk multiple myeloma. Nicola Giuliani, PhD MD Associate Professor of Hematology University of Parma
Biology of high risk multiple myeloma Nicola Giuliani, PhD MD Associate Professor of Hematology University of Parma Hallmarks of high-risk multiple myeloma (MM) 20-30% 1,2 Clinical aggressive behaviour
More informationMyeloma Genetics what do we know and where are we going?
in partnership with Myeloma Genetics what do we know and where are we going? Dr Brian Walker Thames Valley Cancer Network 14 th September 2015 Making the discoveries that defeat cancer Myeloma Genome:
More informationREVIEWS 1. Genomic complexity of multiple myeloma and its clinical implications
Genomic complexity of multiple myeloma and its clinical implications Salomon Manier 1,, Karma Z. Salem 1,, Jihye Park 1,, Dan A. Landau 3,, Gad Getz,5 and Irene M. Ghobrial 1, Abstract Multiple myeloma
More informationManagement of high-risk disease
Management of high-risk disease Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria: BMS,
More informationMyeloma cytogenetics: a personal and historical perspective. Fiona Ross UKMF 19/03/2014
Myeloma cytogenetics: a personal and historical perspective Fiona Ross UKMF 19/03/2014 Chromosome abnormalities in myeloma Abnormal myeloma karyotypes started to be published in 1970s but many cases throughout
More informationMolecular Pathogenesis of Multiple Myeloma:
Molecular Pathogenesis of Multiple Myeloma: Ig translocations hyperdiploid vs non-hyperdiploid CYCLIN D dysregulation other oncogenic events Michael Kuehl MM: post-germinal center tumor of long-lived BM
More informationHaematology Probes for Multiple Myeloma
Haematology Probes for Multiple Myeloma MULTIPLE MYELOMA Multiple myeloma (MM) is a plasma cell neoplasm, characterised by the accumulation of clonal plasma cells in the bone marrow and by very complex
More information1 Diagnosis and Genetic Classification of Multiple Myeloma
1 Diagnosis and Genetic Classification of Multiple Myeloma INTRODUCTION In the past decade we have seen great advances in our understanding of the genetic abnormalities present in multiple myeloma (MM)
More informationThe Markers That Matter. The Decision That Counts.
The Markers That Matter. The Decision That Counts. Prognostic And Predictive Signatures In Oncology: Bridging From Bench To Bedside Martin van Vliet, MSc, PhD EVP Bioinformatics and Product Development
More informationPersonalizing Myeloma Treatment Drugs and Strategies
Personalizing Myeloma Treatment Drugs and Strategies PD Dr. med. Marc S. Raab Heidelberg University Medical Center & German Cancer Research Center Multiple Myeloma Clonal proliferation of malignant plasma
More informationGenomic analysis of childhood High grade glial (HGG) brain tumors
Genomic analysis of childhood High grade glial (HGG) brain tumors Linda D Cooley Children s Mercy, Kansas City The Children s Mercy Hospital, 2017 Genomic analysis of childhood High grade glial (HGG) brain
More informationMYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival
in partnership with MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival Brian A Walker Centre for Myeloma Research,
More informationP53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse
Blood First Edition Paper, prepublished online August 31, 2004; DOI 10.1182/blood-2004-04-1363 P53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse Prognostic Factor for Patients
More informationSignaling Pathway Profiling in Multiple Myeloma. Marc S. Raab, MD PhD
Signaling Pathway Profiling in Multiple Myeloma Marc S. Raab, MD PhD Intro 1. Chromosomal abnormalities: Primary Secondary Myeloma genomics Hyperdiploidy: Trisomies of odd numbered chromosome (3, 5, 7,
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationRisk Stratification in Newly Diagnosed Transplant-Eligible Multiple Myeloma
Risk Stratification in Newly Diagnosed Transplant-Eligible Multiple Myeloma 2 Megan H. Jagosky, Alankrita Taneja, and Manisha Bhutani 2.1 Introduction Complex interplay between biology, chromosomal abnormalities,
More informationThe Utilization of Karyotyping, ifish, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple Myeloma
DOI:10.22034/APJCP.2017.18.11.3135 The Utilization of Karyotyping, ifish and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple Myeloma RESEARCH ARTICLE The Utilization of Karyotyping,
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationGenomic Landscape and Mechanisms of Disease Evolution and Progression in Multiple Myeloma
Genomic Landscape and Mechanisms of Disease Evolution and Progression in Multiple Myeloma Malin Hultcrantz, MD, PhD, and Ola Landgren, MD, PhD Abstract Multiple myeloma (MM) is a plasma cell malignancy,
More informationPublished Ahead of Print on November 8, 2013, as doi: /haematol Copyright 2013 Ferrata Storti Foundation.
Published Ahead of Print on November 8, 2013, as doi:10.3324/haematol.2013.088211. Copyright 2013 Ferrata Storti Foundation. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with
More informationMultiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD
Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD Department of Oncology & Hematology AZ Nikolaas Iridium Kanker Netwerk Introduction Multiple myeloma = Kahler s disease Dr.
More informationMolecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA
Molecular Genetics of Paediatric Tumours Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA Financial Disclosure NanoString - conference costs for
More informationThe role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia
The role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia Adrian Zordan, Meaghan Wall, Ruth MacKinnon, Pina D Achille & Lynda Campbell Victorian Cancer Cytogenetics Service (VCCS)
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationIntroduction to Cancer Biology
Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.
More informationThis is a repository copy of APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
This is a repository copy of APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/87492/
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationMultiple Myeloma: diagnosis and prognostic factors. N Meuleman May 2015
Multiple Myeloma: diagnosis and prognostic factors N Meuleman May 2015 Diagnosis Diagnostic assessment of myeloma: what should we know? Is it really a myeloma? Is there a need for treatment? What is the
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version: CLLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017
More informationThis is a repository copy of Neutral tumor evolution in myeloma is associated with poor prognosis.
This is a repository copy of Neutral tumor evolution in myeloma is associated with poor prognosis. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/121045/ Version: Accepted
More informationRetrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma
930 Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma NIAN LIU, HEBING ZHOU, GUANGZHONG YANG, CHUANYING GENG, YUAN JIAN, HUAN GUO and WENMING CHEN Department
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationGenomic complexity and arrays in CLL. Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy
Genomic complexity and arrays in CLL Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy Clinical relevance of genomic complexity (GC) in CLL GC has been identified as a critical negative
More informationBCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos
BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos Ph like ALL BCR ABL1 like acute lymphoblastic leukemia (ALL)
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationPathology of the indolent B-cell lymphomas Elias Campo
Pathology of the indolent B-cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas Antigen selection NAIVE -B LYMPHOCYTE MEMORY B-CELL MCL FL LPL MZL CLL Small cell
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationCytogenetics 101: Clinical Research and Molecular Genetic Technologies
Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Topics for Today s Presentation 1 Classical vs Molecular Cytogenetics 2 What acgh? 3 What is FISH? 4 What is NGS? 5 How can these
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationUltra High-Risk Myeloma
UNDERSTANDING AND MANAGING ULTRA HIGH-RISK HEMATOLOGIC MALIGNANCIES Ultra High-Risk Myeloma Hervé Avet-Loiseau 1 1 Laboratoire d Hématologie, Institut de Biologie, Nantes, France Ultra high-risk myeloma
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationOutline. Chromosomal analysis FISH. Chromosomal abnormalities in cancer. Clinical application of cytogenetics. Procedure Nomenclature
Outline Chromosomal analysis Procedure Nomenclature FISH Procedure Probes Multicolor-FISH CGH Chromosomal abnormalities in cancer CML, MPD, MDS, AML, ALL, CLL, myeloma, lymphoma Clinical application of
More informationCytogenetics and FISH Studies in Multiple Myeloma A Retrospective Study from Western India
American Journal of Current Biology Gadhia P et al. American Journal of Current Biology 2014, 2:1-7 American Journal Page 1 of of Current 7 Biology http://www.ivyunion.org/index.php/ajcurrb Vol. 2, Article
More informationKarl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
Expanding on WHO guideline compliant molecular testing of central nervous system tumors by low density whole genome sequencing. Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 14 MAY 1 211 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Molecular Heterogeneity of Multiple Myeloma: Pathogenesis, Prognosis, and Therapeutic Implications Hervé Avet-Loiseau,
More informationChromothripsis: A New Mechanism For Tumorigenesis? i Fellow s Conference Cheryl Carlson 6/10/2011
Chromothripsis: A New Mechanism For Tumorigenesis? i Fellow s Conference Cheryl Carlson 6/10/2011 Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development Cell 144,
More informationmsmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma
msmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma msmart Multiple myeloma is increasingly recognized as more than one disease, characterized by marked cytogenetic,
More informationMolecular classification of plasma cell myeloma
Molecular classification of plasma cell myeloma Society for Hematopathology Companion Meeting March 21, 2010 John D. Shaughnessy, Jr. Myeloma Institute for Research and Therapy Can Genomics Aid in Risk
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationMolecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note
Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note MPEP/MPC Advice Note 2016-02 June 2016 Test evaluated: Tumour Protein p53 (TP53) Molecular Pathology Evaluation Panel
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationReview Article Implications of Heterogeneity in Multiple Myeloma
BioMed Research International, Article ID 232546, 12 pages http://dx.doi.org/10.1155/2014/232546 Review Article Implications of Heterogeneity in Multiple Myeloma Sanjay de Mel, 1 Su Hong Lim, 1 Moon Ley
More informationCCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma
AJCP /CASE REPORT CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma Yuan Miao, MD, 1,2 Pei Lin, MD, 1 Wei Wang, MD, 1 L. Jeffrey Medeiros, MD,
More informationARTICLES. Introduction. Methods. Study design This study is a prospective, non-randomized clinical trial. The trial
Multiple Myeloma ARTICLES Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationDevelopments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA
Developments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA Geneva April 20, 2012 Neuroendocrine tumors of lung Typical
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationSmouldering Myeloma: to treat or not to treat?
Smouldering Myeloma: to treat or not to treat? Massimo Offidani Clinica di Ematologia Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona Definitions and epidemiology 3000-5000 new SMM/year in
More informationInitial Diagnosis and Treatment 81 Male
Case SH2017-0359 Shiraz Fidai 1, Sandeep Gurbuxani 1, Girish Venkataraman 1, Gordana Raca 2, Madina Sukhanova 3, Michelle M Le Beau 3, Y. Lynn Wang 4, Mir Alikhan 4, Megan M.McNerney 4, Yuri Kobzev 4,
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationManagement of Multiple Myeloma
Management of Multiple Myeloma Damian J. Green, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance New Treatment Options Have Improved OS in MM Kumar SK, et al. Blood. 2008;111:2516-2520.
More informationTargeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes KM Kortüm 1,8 *, EK Mai 3,4 *, NH Hanafiah 3 *, CX Shi 1, YX Zhu 1, L Bruins 1, S Barrio 1,
More informationMRC-Holland MLPA. Description version 06; 23 December 2016
SALSA MLPA probemix P417-B2 BAP1 Lot B2-1216. As compared to version B1 (lot B1-0215), two reference probes have been added and two target probes have a minor change in length. The BAP1 (BRCA1 associated
More informationMyeloma and renal failure Future directions. Karthik Ramasamy
Myeloma and renal failure Future directions Karthik Ramasamy Overview Historical perspective & Background Drug interventions & trials OPTIMAL Trial Future directions Burden of disease Upto 40% of newly
More informationReporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
More informationMany Multiple Myelomas: Making More of the Molecular Mayhem
LABORATORY MEDICINE:GENETICS OF LYMPHOID NEOPLASMS IN CLINICAL PRACTICE Many Multiple Myelomas: Making More of the Molecular Mayhem Marta Chesi 1 and P. Leif Bergsagel 1 1 Mayo Clinic, Scottsdale, AZ Multiple
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationDouble hit lymphoma Clinical perspectives
Double hit lymphoma Clinical perspectives Peter Johnson Some definitions, for clarity Double-hit lymphoma (5% of DLBL) Rearranged MYC (8q24) by FISH Plus either rearranged BCL2 (18q21) or BCL6 (3q27) Double-expression
More informationCLL Complete SM Report
Reported: 02/01/2012 Σ CGI ID No:5 Client:r Client Address: CLINICAL DATA: Lymphoma No CBC results provided. CLL Complete SM Report FINAL DIAGNOSIS: CD19+ B cell lymphoma, ZAP-70 + (44%), with borderline
More informationMolecular pathogenesis of multiple myeloma and its premalignant precursor
Molecular pathogenesis of multiple myeloma and its premalignant precursor W. Michael Kuehl, P. Leif Bergsagel J Clin Invest. 2012;122(10):3456-3463. https://doi.org/10.1172/jci61188. Review Series Multiple
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationDisclosures. Outlines. Plasma Cell Neoplasms 10/31/2017. I have nothing to disclose. Pei Lin, M. D. Updated diagnostic criteria (DD)
Plasma cell Neoplasms Disclosures I have nothing to disclose. Pei Lin, M. D. Outlines Updated diagnostic criteria (DD) Myeloma phenotype and MRD detection by MFC Identifying high risk patients MRD, FISH,
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationJMSCR Vol 04 Issue 05 Page May 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 5.88 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: http://dx.doi.org/10.18535/jmscr/v4i5.13 Interphase Fluorescence in Situ Hybridization
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationA novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
Europe PMC Funders Group Author Manuscript Published in final edited form as: Leukemia. 2012 February ; 26(2): 349 355. doi:10.1038/leu.2011.204. A novel prognostic model in myeloma based on co-segregating
More informationApplication of Whole Genome Microarrays in Cancer: You should be doing this test!!
Application of Whole Genome Microarrays in Cancer: You should be doing this test!! Daynna Wolff, Ph.D. Director, Cytogenetics and Genomics Disclosures Clinical Laboratory Director and Employee, Medical
More informationResearch Strategy: 1. Background and Significance
Research Strategy: 1. Background and Significance 1.1. Heterogeneity is a common feature of cancer. A better understanding of this heterogeneity may present therapeutic opportunities: Intratumor heterogeneity
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationSuccessful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy
CASE REPORT Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy Naohiro Sekiguchi 1, Naoki Takezako 1, Akihisa Nagata 1, Miyuki Wagatsuma 2, Satoshi Noto 1, Kazuaki
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More information